SCHEMBL22019345

SCHEMBL22019345

COC(=O)CCC1(C(=O)OC)Cc2ccccc2O1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.38
BACE1 P56817 1/20 0.34
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 2/20 0.33
LMNA P02545 2/20 0.33
MAPT P10636 2/20 0.33
HTT P42858 2/20 0.33
CACNA1C Q13936 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
AKT1 P31749 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4383883 0.83 CYP2D6 (0.39) KDM4EALDH1A1LMNAMAPTHTT
SCHEMBL22019344 0.75 NOTUM (0.43) NOTUMBACE1KDM4EALDH1A1LMNA
SCHEMBL30817420 0.74 L3MBTL1 (0.38) KDM4EALDH1A1LMNAMAPTHTT
SCHEMBL3519499 0.73 POLB (0.50) KDM4EALDH1A1LMNAMAPTHTT
SCHEMBL19586047 0.72 SIRT2 (0.32) KDM4EMAPTSMN1; SMN2
SCHEMBL14350861 0.71 BACE1 (0.44) NOTUMBACE1KDM4EALDH1A1LMNA
SCHEMBL29395374 0.71 DRD2 (0.45) KDM4EALDH1A1LMNAMAPTKMT2A
SCHEMBL8322864 0.70 TSHR (0.44) KDM4EALDH1A1LMNAMAPTHTT
SCHEMBL7420613 0.70 PPARA (0.44) LMNATSHRKMT2ACYP3A4SMN1; SMN2
SCHEMBL3380544 0.70 PPARA (0.44) LMNATSHRKMT2ACYP3A4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-10660968-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A NOTUM 3614/4885BACE1 1584/4885KDM4E 1930/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A NOTUM 3614/4885BACE1 1584/4885KDM4E 1930/4885
US-10660968-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A NOTUM 3614/4885BACE1 1584/4885KDM4E 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.